The latest price target for Cormedix (NASDAQ:CRMD) was reported by Leerink Partners on March 7, 2025. The analyst firm set a price target for $18.00 expecting CRMD to rise to within 12 months (a possible 65.90% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Cormedix (NASDAQ:CRMD) was provided by Leerink Partners, and Cormedix initiated their outperform rating.

There is no last upgrade for Cormedix

There is no last downgrade for Cormedix.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cormedix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cormedix was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.

While ratings are subjective and will change, the latest Cormedix (CRMD) rating was a initiated with a price target of $0.00 to $18.00. The current price Cormedix (CRMD) is trading at is $10.85, which is within the analyst’s predicted range.